Concentration of adipogenic and proinflammatory cytokines in the bone marrow supernatant fluid of osteoporotic women

Journal of Bone and Mineral Research

Volumn 25, Issue 3, 2010, Pages 492-498

  Pino, Ana María ^a   Ríos, Susana ^a   Astudillo, Pablo ^a   Fernández, Mireya ^a   Figueroa, Paula ^a   Seitz, Germán ^b   Rodríguez, J Pablo ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL DR SÓTERO DEL RÍO   (Chile)

Author keywords

Adipokines; Bone marrow fluid; Leptin bioavailability; Osteoporosis; Proinflammatory cytokines

Indexed keywords

ADIPONECTIN; CYTOKINE; INTERLEUKIN 6; LEPTIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; OSTEOPROTEGERIN; TNFRSF11B PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; BONE FRAGILITY; BONE MARROW; BONE MARROW BIOPSY; BONE MARROW CELL; BONE MASS; BONE TISSUE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DONOR; DUAL ENERGY X RAY ABSORPTIOMETRY; EXTRACELLULAR FLUID; FEMALE; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; SUPERNATANT; ADIPOCYTE; ADIPOSE TISSUE; BLOOD; CHEMISTRY; CYTOLOGY; IMMUNOLOGY; INFLAMMATION; OSTEOBLAST; PHOTON ABSORPTIOMETRY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS;

ABSORPTIOMETRY, PHOTON; ADIPOCYTES; ADIPOSE TISSUE; AGED; BIOLOGICAL MARKERS; BONE MARROW; BONE RESORPTION; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; OSTEOBLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; POSTMENOPAUSE;

EID: 77953372591     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.090802     Document Type: Article

References (59)

1. Zipori D. The stem state: mesenchymal plasticity as a paradigm. Curr Stem Cell Res Ther. 2006;1:95-102.
2. Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. Exp Biol Med. 2001;226:507-520.
3. Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med. 2006;119:3S-11S.
4. Wiig H, Berggreen E, Borge BA, Iversen PO. Demonstration of altered signaling responses in bone marrow extracellular fluid during increased hematopoiesis in rats using a centrifugation method. Am J Physiol Heart Circ Physiol. 2004;286:H2028-H2034. (Pubitemid 38525495)
5. Iversen PO, Wiig H. tumor necrosis factor α and adiponectin in bone marrow interstitial fluid from patients with acute myeloid leukemia inhibit normal hematopoiesis. Clin Cancer Res. 2005;11:6793-6799.
6. Lee WY, Kang MI, Oh ES, et al. The role of cytokines in the changes in bone turnover following bone marrow transplantation. Osteoporos Int. 2002;13:62-68. (Pubitemid 34162509)
7. Khosla S, Peterson JM, Egan K, Jones JD, Riggs BL. Circulating cytokine levels in osteoporotic and normal women. J Clin Endocrinol Metab. 1994;79:707-611. (Pubitemid 24286389)
8. Nuttall ME, Gimble JM. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol. 2004;4:290-294.
9. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Prac Rheumatol. 2006;2:35-43.
10. Rodríguez JP, Astudillo P, Ríos S, Pino AM. Involvement of adipogenic potential of human bone marrow mesenchymal stem cells (MSCs) in osteoporosis. Stem Cell Res Ther. 2008;3:208-218.
11. Pittenger MF, Mackay AM, Beck SC, et al. Multineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147. (Pubitemid 29282067)
12. Meunier P, Aaron J, Edouard C, Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue: a quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res. 1971;80:147-154.
13. Ogawa S, Urano T, Hosoi T, et al. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARγ expression in osteoblasts. Biochem Biophys Res Commun. 1999;260:122-126. (Pubitemid 29351795)
14. Bodine PV, Zhao W, Kharode YP, et al. The Wnt antagonist secreted frizzled related protein 1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol. 2004;18:1222-1237. (Pubitemid 38591287)
15. Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA. 2005;102:3324-3329.
16. Schäffler A, Müller-Ladner U, Schölmerich J, Büchler C. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev. 2006;27:449-467. (Pubitemid 44213227)
17. Yokota T, Meka CS, Medina KL, et al. Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins. J Clin Invest. 2002;109:1303-1310. (Pubitemid 34546894)
18. Richards JB, Valdes AM, Burling K, Perks UC, Spector TD. Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab. 2007;92:1517-1523. (Pubitemid 46556433)
19. Nishida M, Funahashi T, Shimomura I. Pathophysiological significance of adiponectin. Med Mol Morphol. 2007;40:55-67.
20. Thomas T, Burguera B. Is leptin the link between fat and bone mass? J Bone Miner Res. 2002;17:1563-1569.
21. Laharrague P, Truel N, Fontanilles AM, Corberand JX, Penicaud L, Casteilla L. Regulation by cytokines of leptin expression in human bone marrow adipocytes. Horm Metab Res. 2000;32:381-385. (Pubitemid 32044248)
22. Lammert A, Kiess W, Bottner A, Glasow A, Kratzsch J. Soluble leptin receptor represents the main leptin binding activity in human blood. Biochem Biophys Res Commun. 2001;283:982-988. (Pubitemid 32924677)
23. Sinha MK, Opentanova I, Ohannesian JP, et al. Evidence of free and bound leptin in human circulation: studies in lean and obese subjects and during short-term fasting. J Clin Invest. 1996;98:1277-1282. (Pubitemid 26322051)
24. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986;319:516-518.
25. Ishimi Y, Miyaura C, Jin CH, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol. 1990;145:3297-3303.
26. Mundy GR. Osteoporosis and inflammation. Nutr Rev. 2007;65:S147-151.
27. Giuliani N, Sansoni P, Girasole G, et al. Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes. Exp Gerontol. 2001;36:547-57. (Pubitemid 32201509)
28. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29:155-192. (Pubitemid 351519689)
29. Mezquita-Raya P, de la Higuera M, Fernández García D, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int. 2005;16:1368-1374. (Pubitemid 41532089)
30. Schett G, Kiechl S, Redlich K, et al. Soluble RANKL and risk of nontraumatic fracture. JAMA. 2004;291:1108-1113. (Pubitemid 38541688)
31. Rodríguez JP, Garat S, Gajardo H, Pino AM, Seitz G. Abnormal osteogenesis in osteoporotic patients is reflected by altered mesenchymal stem cell dynamics. J Cell Biochem. 1999;75:414-423. (Pubitemid 29521650)
32. Raisz LG. The osteoporosis revolution. Ann Intern Med. 1997;126:458-462.
33. Indridason OS, Franzson L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int. 2005;16:417-423. (Pubitemid 40487400)
34. Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R. Establishing a reference range for bone turnover markers in young, healthy women. Bone. 2008;42:623-630.
35. Tsuda E, Goto M, Mochizuki SI, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 1997;234:137-142. (Pubitemid 27267548)
36. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998;95:3597-3602. (Pubitemid 28173173)
37. Hess R, Pino AM, Ríos S, Fernández M, Rodríguez JP. High affinity leptin receptors are present in human mesenchymal stem cells (MSCs) derived from control and osteoporotic donors. J Cell Biochem. 2005;94:50-57. (Pubitemid 41420323)
38. Odabaşi E, Ozata M, Turan M, et al. Plasma leptin concentrations in postmenopausal women with osteoporosis. Eur J Endocrinol. 2000;142:170-173. (Pubitemid 30121031)
39. Shaarawy M, Abassi AF, Hassan H, Salem ME. Relationship between serum leptin concentrations and bone mineral density as well as biochemical markers of bone turnover in women with postmenopausal osteoporosis. Fertil Steril. 2003;79:919-924. (Pubitemid 36385014)
40. Weiss LA, Barrett-Connor E, von Mühlen D, Clark P. Leptin predicts BMD and bone resorption in older women but not older men: the Rancho Bernardo Study. J Bone Miner Res. 2006;21:758-764.
41. Yano K, Tsuda N, Kobayashi F, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res. 1999;14:518-527. (Pubitemid 29153384)
42. Riggs BL, Khosla S, Atkinson EJ, Dunstan CR, Melton LJ III. Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. Osteoporos Int. 2003;14:728-733. (Pubitemid 37295834)
43. Abrahamsen B, Bopnnevie-Nielsen V, Nils Ebbesen E, Gram J, Beck-Nielsen H. Cytokines and bone loss in a 5-year longitudinal study-hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. J Bone Miner Res. 2000;15:1545-1554. (Pubitemid 30484524)
44. Nakchbandi I, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2002;87:4946-4951. (Pubitemid 35316330)
45. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79-83. (Pubitemid 29299050)
46. Hotta K, Funahashi T, Arita Y, et al. Plasma concentration of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595-1599. (Pubitemid 30353893)
47. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/BMP signaling pathways. Aging Cell. 2004;3:379-389. (Pubitemid 40246708)
48. Zayzafon M, Gathings WE, McDonald JM. Modeled microgravity inhibits osteogenic differentiation of human mesenchymal stem cells and increases adipogenesis. Endocrinology. 2004;145:2421-2432. (Pubitemid 38535071)
49. Astudillo P, Ríos S, Pastenes L, Pino AM, Rodríguez JP. Increased adipogenesis of osteoporotic human-msenchymal stem cells (MSCs) characterizes by impaired leptin action. J Cell Biochem. 2008;103:1054-1065. (Pubitemid 351342599)
50. Hozumi A, Osaki M, Goto H, Sakamoto K, Inokuchi S, Shindo H. Bone marrow adipocytes support dexamethasone-induced osteoclast differentiation. Biochem Biophys Res Commun. 2009;382:780-784.
51. Holloway WR, Collier FM, Aitken CJ, et al. Leptin inhibits osteoclast generation. J Bone Miner Res. 2002;17:200-209.
52. Martin A, de Vittoris R, David V, et al. Leptin modulates both resorption and formation while preventing disuse-induced bone loss in tail-suspended female rats. Endocrinology. 2005;146:3652-3659. (Pubitemid 41058137)
53. Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab. 2003;14:398-403. (Pubitemid 37392211)
54. Uotani S, Bjorbaek C, Tornoe J, Flier JS. Functional properties of leptin receptor isoforms: internalization and degradation of leptin and ligand-induced receptor down regulation. Diabetes. 1999;48:279-286. (Pubitemid 29061099)
55. Wang ZW, Zhou YT, Kakuma T, et al. Comparing the hypothalamic and extrahypothalamic actions of endogenous hyperleptinemia. Proc Natl Acad Sci USA. 1999;96:10373-10378. (Pubitemid 29422565)
56. Martin RL, Perez E, He YJ, Dawson R Jr, Millard WJ. Leptin resistance is associated with hypothalamic leptin receptor mRNA and protein downregulation. Metabolism. 2000;49:1479-1484.
57. Sandhofer A, Laimer M, Ebenbichler CF, Kaser S, Paulweber B, Patsch JR. Soluble leptin receptor and soluble receptor-bound fraction of leptin in the metabolic syndrome. Obes Res. 2003;11:760-768. (Pubitemid 41151602)
58. Chan JL, Bluher S, Yiannakouris N, Suchard MA, Kratzsch J, Mantzoros CS. Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes. 2002;51:2105-2112. (Pubitemid 34729014)
59. Jiang L-S, Zhang Z-M, Jiang S-D, Chen W-H, Dai L-Y. Differential bone metabolism between postmenopausal women with osteoarthritis and osteoporosis. J Bone Miner Res. 2008;23:475-483. (Pubitemid 351501887)